更新于：2024-11-01

Paraneoplastic Polyneuropathy

副肿瘤性多发性神经病

更新于：2024-11-01

基本信息

别名

Carcinomatous neuropathy、Carcinomatous peripheral neuropathy、Neuropathies, Paraneoplastic

+ [82]

简介

A diffuse or multifocal peripheral neuropathy related to the remote effects of a neoplasm, most often carcinoma or lymphoma. Pathologically, there are inflammatory changes in peripheral nerves. The most common clinical presentation is a symmetric distal mixed sensorimotor polyneuropathy. (Adams et al., Principles of Neurology, 6th ed, p1334)

关联

项与副肿瘤性多发性神经病相关的临床试验

IRCT20240729062576N1 / RecruitingN/AIIT

Effect of a supportive educational intervention through virtual social networks on Neuropathy in cancer patients undergoing chemotherapy

开始日期2024-08-15

申办/合作机构

Arak University of Medical Sciences

NCT06373211 / Not yet recruiting临床2期IIT

Early Immunotherapy With Intravenous Immunoglobulin, Cyclophosphamide and Methylprednisolone in Patients With Anti-Hu-associated Paraneoplastic Sensory Neuronopathy

Paraneoplastic Neurological Syndromes are rare autoimmune complications linked to the presence of systemic cancer. Despite their autoimmune origin, they have historically shown little response to immunotherapy. The reason for this failure is probably related to too late administration of immunotherapy, at a stage where the inflammation has already disappeared and irreversible neuronal loss has occurred. The protocol focuses on patients with anti-Hu antibody sensory neuronopathy. This single arm trial consists of an early immunotherapy combining Intravenous Immunoglobulin (IVIG) for 3 months, cyclophosphamide and methylprednisolone for 6 months, at the rate of 1 cycle per month. The percentage of patients with clinical improvement will be evaluated (ONLS) at 3 months. The tolerance of the treatment will also be evaluated as well as other functional scales at 3 and 6 months.

开始日期2024-06-01

申办/合作机构

Assistance Publique des Hôpitaux de Paris SA

NCT05866653 / Recruiting临床2期IIT

Effect of Lidocaine Transdermal Patch as Add-On Therapy in Treatment of Oxaliplatin Induced Peripheral Neuropathy in Colorectal Cancer Patients

Oxaliplatin (OXA) is a third-generation platinum-based chemotherapeutic drug with better efficacy for colorectal carcinoma (CRC). Oxaliplatin-induced peripheral neuropathy (OIPN) is one of the most frequent dose-limiting or even treatment-terminating side effects that impair optimal treatment regimens in a significant proportion of patients from 19% to over 85%. Thus, OIPN impacts the quality of life and the patient's survival. OIPN is a clinical challenge and healthcare professionals are facing this challenge with a limited selection of analgesics and nonpharmacological therapies. Pregabalin is a structural derivative of GABA and is one of the effective treatment modalities for OIPN. It binds with high affinity to the alpha2-delta site of voltage-gated calcium channels in central nervous system tissues and inhibits neurotransmitter release, thus producing anti-nociceptive and anti-seizure effects.

开始日期2023-03-25

申办/合作机构

Bangabandhu Sheikh Mujib Medical University

100 项与副肿瘤性多发性神经病相关的临床结果

登录后查看更多信息

100 项与副肿瘤性多发性神经病相关的转化医学

登录后查看更多信息

0 项与副肿瘤性多发性神经病相关的专利（医药）

登录后查看更多信息

562

项与副肿瘤性多发性神经病相关的文献（医药）

2024-10-01·Seminars in Oncology Nursing

Prazosin as an Adjuvant to Increase Effectiveness of Duloxetine in a Rat Model of Oxaliplatin-Induced Peripheral Neuropathy

Article

作者: Ayyash, Naji ; Smith, Ellen M Lavoie ; Holden, Janean E ; Wagner, Monica A

OBJECTIVESDuloxetine, the only American Society of Clinical Oncology (ASCO) treatment recommended for chemotherapy-induced peripheral neuropathy (CIPN) in cancer survivors, is not effective for 40% of survivors. This study examined the ability of a duloxetine-prazosin combination to prevent the development of allodynia and hyperalgesia in a rat model of oxaliplatin-induced peripheral neuropathy (OPIN).METHODSFemale (n = 24) and male (n = 41) rats were started on duloxetine (15 mg), prazosin (2 mg), or a duloxetine-prazosin combination one week prior to administration of the chemotherapy drug, oxaliplatin, and continued the duloxetine-prazosin combination for 32 days. Behavioral testing for mechanical allodynia and mechanical hyperalgesia was done with selected von Frey filaments over the course of the study.RESULTSOverall percent paw withdrawal for rats that received the duloxetine-prazosin combination was significantly lower in female (p < .001 for both conditions) and male (p = .029 for allodynia; p < .001 for hyperalgesia) than those that received water. No significant posttreatment differences were found for allodynia or hyperalgesia between rats treated with duloxetine and rats that received the duloxetine-prazosin combination in either sex.CONCLUSIONSThese finding provide preliminary evidence that a duloxetine-prazosin combination can prevent the posttreatment development of allodynia and hyperalgesia in both male and female rats; however, the results suggest that the duloxetine-prazosin combination is no more efficacious than duloxetine alone in preventing chronic OIPN.IMPLICATIONS FOR NURSING PRACTICEThe profession of nursing is built on clinical practice supported by scientific research. The current study addressed the clinical practice problem of prevention and management of painful OIPN, which is a priority area in oncology nursing.

2024-10-01·Supportive Care in Cancer

Oxaliplatin-induced peripheral neuropathy with hepatic arterial versus intravenous infusion in metastatic colorectal cancer

Article

作者: Smolenschi, Cristina ; Goéré, Diane ; Tselikas, Lambros ; Hollebecque, Antoine ; Boilève, Alice ; Ducreux, Michel ; Taïeb, Julien ; de Sevilla, Elena Fernandez ; Gelli, Maximiliano ; Boige, Valérie ; Valéry, Marine ; Bonnet, Baptiste ; Tanguy, Marie-Laure ; Malka, David

BACKGROUNDOxaliplatin, a major drug in metastatic colorectal cancer (mCRC), is responsible for cumulative, dose-limiting peripheral neuropathy (PN). Whether the hepatic arterial infusion (HAI) route can limit oxaliplatin-induced PN in comparison with the intravenous (IV) route has not been specifically explored so far.METHODSWe compared the frequency and severity of PN in oxaliplatin-naive patients with mCRC included in trials that evaluated treatment with oxaliplatin administered either by HAI (ACCORD 04, CHOICE, OSCAR, and PACHA-01 trials) or by IV route (FFCD 2000-05 trial). We retrieved anonymized, prospectively collected data from trial databases for the ACCORD 04, CHOICE, and FFCD 2000-05 trials and through a review of Gustave Roussy patients' electronic medical records for PACHA-01 and OSCAR trials. The primary endpoint was the incidence of clinically significant PN (grades 2 to 4) according to the cumulative dose of oxaliplatin received. Secondary endpoints were time to onset of neuropathy as a function of the cumulative dose of oxaliplatin, discontinuation of oxaliplatin for neurotoxicity, and safety.RESULTSA total of 363 patients were included (IV, 300; HAI, 63). In total, 180 patients in the IV group (60%) and 30 patients in the HAI group (48%) developed clinically significant PN, with no significant difference between the two groups (p = 0.23). No difference was shown in the time to onset of PN either (p = 0.23).CONCLUSIONThe administration of oxaliplatin HAI rather than IV in the treatment of mCRC does not reduce the incidence, precocity, and severity of PN.

2024-09-19·British journal of pharmacology

Contribution of T-type calcium channel isoforms to cold and mechanical sensitivity in naïve and oxaliplatin-treated mice of both sexes.

Article

作者: Snutch, Terrance P ; Hildebrand, Michael ; Santin, José Roberto ; Zamponi, Gerald W ; Souza, Ivana A ; Gadotti, Vinicius M ; David, Laurence S ; Antunes, Flavia T T ; Quintão, Nara Lins Meira ; Gandini, Maria A

BACKGROUND AND PURPOSEThe chemotherapy agent oxaliplatin can give rise to oxaliplatin-induced peripheral neuropathy (OIPN). Here, we investigated whether T-type calcium channels (Ca_v3) contribute to OIPN.EXPERIMENTAL APPROACHWe chronically treated mice with oxaliplatin and assessed pain responses and changes in expression of Ca_v3.2 calcium channels. We also tested the effects of T-type channel blockers on cold sensitivity in wild-type and Ca_v3.2 null mice.KEY RESULTSOxaliplatin treatment led to mechanical and cold hypersensitivity in male and female mice. Mechanical hypersensitivity persisted in Ca_v3.2 null mice of both sexes. Intraperitoneal or intrathecal delivery of pan T-type channel inhibitors attenuated mechanical hypersensitivity in wild-type but not Ca_v3.2 null mice. Remarkably cold hypersensitivity occurred in female but not male Ca_v3.2 null mice even without oxaliplatin treatment. Unexpectedly, intrathecal, intraplantar or intraperitoneal delivery of T-type channel inhibitors Z944 or TTA-P2 transiently induced cold hypersensitivity in both male and female wild-type mice. Acute knockdown of specific Ca_v3 isoforms revealed that the depletion of Ca_v3.1 in males and depletion of either Ca_v3.1 or Ca_v3.2 in females triggered cold hypersensitivity. Finally, reducing Ca_v3.2 expression by disrupting the interactions between Ca_v3.2 and the deubiquitinase USP5 with the small organic molecule II-2 reversed oxaliplatin-induced mechanical and cold hypersensitivity and importantly did not trigger cold allodynia.CONCLUSION AND IMPLICATIONSAltogether, our data indicate that T-type channels differentially contribute to the regulation of cold and mechanical hypersensitivity, and raise the possibility that T-type channel blockers could promote cold allodynia.